source
- Lilly beats forecasts while Novo Nordisk misses sales and trial targetsEli Lilly reported second-quarter revenue of nearly $23 billion, up 48% year-over-year, easily surpassing analysts’ $20.6 billion estimate. The boost came from continued strength of its tirzepatide…
- FDA approves Takeda’s orexin receptor agonist for narcolepsy, opening new drug classThe FDA has granted approval to Takeda's novel narcolepsy medication, the first orexin receptor agonist to receive clearance. The twice‑daily pill, marketed as Orzeyful, is indicated for narcoleps…